REVIEW article
Front. Immunol.
Sec. Molecular Innate Immunity
PRMT3 at the Crossroads of Inflammation: Dual Roles in Metabolic Reprogramming and Immune Dysregulation in Chronic Diseases
Provisionally accepted
- 1Dalian University, Dalian, China
- 2Department of Neurology, Affiliated Hospital of YanBian University, jilin, China
- 3Affiliated Zhuhai Hospital, Southern Medical University, Zhuhai Hospital of Integrated Traditional Chinese & Western Medicine, Zhuhai 519000, Guangdong, China., Zhuhai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Protein arginine methyltransferase 3, a type I PRMT family member, plays pleiotropic roles in chronic inflammatory diseases through its catalysis of asymmetric dimethylarginine modifications. Chronic inflammation, marked by metabolic dysregulation, immune dysfunction, and tissue fibrosis, drives diverse pathologies including non-alcoholic fatty liver disease, chronic kidney disease, and atherosclerosis. In this review, we comprehensively dissect the multifaceted contributions and molecular mechanisms of PRMT3 in inflammation-associated disorders. Mechanistically, PRMT3 aggravates inflammatory-metabolic dyshomeostasis in chronic inflammation via LXRα/HIF-1α methylation, thereby accelerating vascular calcification and fibrosis. Paradoxically, it simultaneously suppresses antiviral immunity and facilitates tumor immune evasion, underscoring its dual role as a molecular "double-edged sword". Notably, PRMT3 inhibitors such as SGC707 demonstrate preclinical promise in modulating lipid metabolism and curtailing tumor progression. However, challenges persist regarding tissue specificity and off-target toxicity, necessitating further refinement. Collectively, these results provide a new molecular basis for therapeutic approaches targeting PRMT3.
Keywords: Protein arginine methyltransferase 3, Chronic inflammatory diseases, Asymmetric dimethylarginine, SGC707 inhibitor, metabolic reprogramming
Received: 11 Jul 2025; Accepted: 30 Nov 2025.
Copyright: © 2025 Hou, Meng, Zhang, Chen, Wang, Zheng and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zebo Jiang
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.